MX2020004897A - Acidos nucleicos para inhibir la expresion de lpa en una celula. - Google Patents

Acidos nucleicos para inhibir la expresion de lpa en una celula.

Info

Publication number
MX2020004897A
MX2020004897A MX2020004897A MX2020004897A MX2020004897A MX 2020004897 A MX2020004897 A MX 2020004897A MX 2020004897 A MX2020004897 A MX 2020004897A MX 2020004897 A MX2020004897 A MX 2020004897A MX 2020004897 A MX2020004897 A MX 2020004897A
Authority
MX
Mexico
Prior art keywords
nucleic acids
inhibiting expression
expression
relates
products
Prior art date
Application number
MX2020004897A
Other languages
English (en)
Inventor
Lucas Bethge
Judith Hauptmann
Christian Frauendorf
Adrien Weingärtner
Sibylle Dames
Steffen Schubert
Stephan Tenbaum
David Anthony Rider
Original Assignee
Silence Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17201449.0A external-priority patent/EP3483270A1/en
Application filed by Silence Therapeutics Gmbh filed Critical Silence Therapeutics Gmbh
Publication of MX2020004897A publication Critical patent/MX2020004897A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a productos y composiciones y sus usos. En particular, la invencion se relaciona a productos de ácido nucleico que interfieren con la expresion del gen LPA o inhiben su expresion para uso como tratamiento, prevención o reduccion del riesgo de sufrir enfermedad cardiovascular tal como cardiopatía coronaria o estenosis de la aorta o accidente cardiovascular o cualquier otro trastorno, patología o síndrome relacionado con niveles elevados de partículas que contienen Lp(a).
MX2020004897A 2017-11-13 2018-11-13 Acidos nucleicos para inhibir la expresion de lpa en una celula. MX2020004897A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17201449.0A EP3483270A1 (en) 2017-11-13 2017-11-13 Products and compositions
EP18179175.7A EP3483271A3 (en) 2017-11-13 2018-06-21 Products and compositions
GB201815915 2018-09-28
PCT/EP2018/081106 WO2019092283A1 (en) 2017-11-13 2018-11-13 Nucleic acids for inhibiting expression of lpa in a cell

Publications (1)

Publication Number Publication Date
MX2020004897A true MX2020004897A (es) 2020-10-05

Family

ID=66439085

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004897A MX2020004897A (es) 2017-11-13 2018-11-13 Acidos nucleicos para inhibir la expresion de lpa en una celula.

Country Status (22)

Country Link
US (2) US11319537B2 (es)
EP (2) EP4219716A3 (es)
JP (1) JP7245254B2 (es)
KR (1) KR102553382B1 (es)
CN (1) CN111465694A (es)
AU (1) AU2018363840B2 (es)
BR (1) BR112020009152A2 (es)
CA (1) CA3081905C (es)
DK (1) DK3710586T3 (es)
ES (1) ES2938193T3 (es)
FI (1) FI3710586T3 (es)
HR (1) HRP20230127T1 (es)
HU (1) HUE061265T2 (es)
IL (1) IL274503A (es)
LT (1) LT3710586T (es)
MX (1) MX2020004897A (es)
PL (1) PL3710586T3 (es)
RS (1) RS63955B1 (es)
SG (1) SG11202003230UA (es)
SI (1) SI3710586T1 (es)
WO (1) WO2019092283A1 (es)
ZA (1) ZA202003371B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3389862T3 (pl) 2015-12-16 2024-03-04 6K Inc. Sferoidalne metale podlegające odwodornieniu oraz cząstki stopów metali
WO2018185241A1 (en) * 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Products and compositions
US11661603B2 (en) 2018-01-16 2023-05-30 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting ALDH2 expression
PL3880818T3 (pl) * 2018-11-13 2023-01-23 Silence Therapeutics Gmbh Kwasy nukleinowe do hamowania ekspresji LPA w komórce
SG11202110896WA (en) * 2019-04-04 2021-10-28 Dicerna Pharmaceuticals Inc Compositions and methods for inhibiting gene expression in the central nervous system
SG11202111576QA (en) 2019-04-30 2021-11-29 6K Inc Mechanically alloyed powder feedstock
CN114641462A (zh) 2019-11-18 2022-06-17 6K有限公司 用于球形粉末的独特原料及制造方法
AU2020399636A1 (en) * 2019-12-09 2022-06-02 Amgen Inc. RNAi constructs and methods for inhibiting LPA expression
CA3180426A1 (en) 2020-06-25 2021-12-30 Richard K. Holman Microcomposite alloy structure
JP7476422B2 (ja) 2020-08-05 2024-04-30 ディセルナ ファーマシューティカルズ インコーポレイテッド Ｌｐａ発現を阻害するための組成物及び方法
US11963287B2 (en) 2020-09-24 2024-04-16 6K Inc. Systems, devices, and methods for starting plasma
JP2023545502A (ja) 2020-10-16 2023-10-30 サノフイ リポタンパク質（ａ）を阻害するためのｒｎａ組成物および方法
KR20230095080A (ko) 2020-10-30 2023-06-28 6케이 인크. 구상화 금속 분말을 합성하는 시스템 및 방법
MX2023005198A (es) * 2020-11-05 2023-05-16 Amgen Inc Metodos para tratar la enfermedad cardiovascular aterosclerotica con constructos de iarn dirigidos a lpa.
EP4237561A1 (en) 2020-12-23 2023-09-06 Argonaute Rna Limited Treatment of cardiovascular disease
CA3229020A1 (en) 2021-09-14 2023-03-23 Stella PELENGARIS Treatment of cardiovascular disease
AU2022393572A1 (en) * 2021-11-18 2024-04-11 Novartis Ag Compounds targeting pmp22 for the treatment of charcot-marie-tooth disease
WO2023097291A1 (en) * 2021-11-24 2023-06-01 Adarx Pharmaceuticals, Inc. Complement factor b-modulating compositions and methods of use thereof
CN114703184A (zh) * 2022-03-11 2022-07-05 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
WO2023220744A2 (en) 2022-05-13 2023-11-16 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2024006999A2 (en) 2022-06-30 2024-01-04 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
WO2009151644A2 (en) * 2008-06-13 2009-12-17 Yale University Small molecule inhibitors of autotaxin methods of use
EP2853597B1 (en) * 2012-05-22 2018-12-26 Olix Pharmaceuticals, Inc. Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
WO2016149020A1 (en) * 2015-03-17 2016-09-22 Arrowhead Research Corporation Rna interference agents
JOP20210043A1 (ar) * 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
EP3228326A1 (en) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Nucleic acid linked to a trivalent glycoconjugate
WO2018185241A1 (en) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Products and compositions
CA3118327A1 (en) 2017-11-13 2019-05-16 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of aldh2 in a cell
PL3880818T3 (pl) 2018-11-13 2023-01-23 Silence Therapeutics Gmbh Kwasy nukleinowe do hamowania ekspresji LPA w komórce

Also Published As

Publication number Publication date
RS63955B1 (sr) 2023-02-28
EP4219716A3 (en) 2024-03-27
AU2018363840B2 (en) 2022-09-29
US20210123048A1 (en) 2021-04-29
JP2021502120A (ja) 2021-01-28
US20220290144A1 (en) 2022-09-15
CA3081905A1 (en) 2019-05-16
DK3710586T3 (da) 2023-01-23
CN111465694A (zh) 2020-07-28
WO2019092283A1 (en) 2019-05-16
KR20200088392A (ko) 2020-07-22
ES2938193T3 (es) 2023-04-05
BR112020009152A2 (pt) 2020-10-27
LT3710586T (lt) 2023-02-27
HRP20230127T1 (hr) 2023-03-31
CA3081905C (en) 2023-10-03
ZA202003371B (en) 2023-08-30
EP3710586B1 (en) 2022-11-23
SI3710586T1 (sl) 2023-03-31
EP4219716A2 (en) 2023-08-02
US11319537B2 (en) 2022-05-03
JP7245254B2 (ja) 2023-03-23
IL274503A (en) 2020-06-30
SG11202003230UA (en) 2020-05-28
EP3710586A1 (en) 2020-09-23
AU2018363840A1 (en) 2020-04-16
HUE061265T2 (hu) 2023-06-28
PL3710586T3 (pl) 2023-03-20
KR102553382B1 (ko) 2023-07-07
FI3710586T3 (fi) 2023-03-02

Similar Documents

Publication Publication Date Title
MX2020004897A (es) Acidos nucleicos para inhibir la expresion de lpa en una celula.
CL2021001225A1 (es) Ácidos nucleicos para inhibir la expresión de lpa en una célula
BR112016029041A2 (pt) terapia de combinação com inibidores de glutaminase
CO2017004728A2 (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa)
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
PE20181139A1 (es) Composiciones y metodos para inhibir la expresion genica de lpa
ECSP17021754A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
NI201700055A (es) 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
BR112018004970A2 (pt) oligômero antissenso, composição farmacêutica, método para tratamento de distrofia muscular, e, uso do oligômero antissenso ou sal farmaceuticamente aceitável ou hidrato do mesmo.
CO2018012433A2 (es) Composiciones y métodos para tratar enfermedades asociadas con repeticiones de trinucleótidos en el factor de transcripción cuatro
MX2020004898A (es) Ácidos nucleicos para inhibir la expresión de un gen diana que comprende enlaces fosforoditioato.
UY34773A (es) Ácidos indanoiloxidihidrobenzofuranilacéticos como moduladores de la actividad de gpr40, composiciones que los contienen y sus usos
PH12017501692A1 (en) Solid forms of menaquinols
CO2022009787A2 (es) Agentes de arni del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72), composiciones y métodos de uso de los mismos
CO2021002691A2 (es) Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1)
CL2017000118A1 (es) Métodos y composiciones para tratar desórdenes relacionados con el vih
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
MX368689B (es) Derivados de citocromo p450 (cyp)-eicosanoide novedosos.
BR112017004253A2 (pt) agentes antivirais e suas utilizações
BR112018070194A2 (pt) composto e composição para uso
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.
EA202090091A1 (ru) Соль (ss)-аденозилметионина с гексафосфатом инозитола и способ ее получения
MD3880818T2 (ro) Acizi nucleici pentru inhibarea expresei LPA într-o celulă
Minulina et al. Modern youth slang
Printz New guidelines aim to improve personalized cancer care.